Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis.

Nicaise AM, Wagstaff LJ, Willis CM, Paisie C, Chandok H, Robson P, Fossati V, Williams A, Crocker SJ.

Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9030-9039. doi: 10.1073/pnas.1818348116. Epub 2019 Mar 25.

2.

RNA-seq analysis reveals differences in transcript abundance between cultured and sand fly-derived Leishmania infantum promastigotes.

Alcolea PJ, Alonso A, Baugh L, Paisie C, Ramasamy G, Sekar A, Sur A, Jiménez M, Molina R, Larraga V, Myler PJ.

Parasitol Int. 2018 Aug;67(4):476-480. doi: 10.1016/j.parint.2018.03.008. Epub 2018 Mar 30.

PMID:
29609036
3.

The ubiquitous 'cancer mutational signature' 5 occurs specifically in cancers with deleted FHIT alleles.

Volinia S, Druck T, Paisie CA, Schrock MS, Huebner K.

Oncotarget. 2017 Nov 6;8(60):102199-102211. doi: 10.18632/oncotarget.22321. eCollection 2017 Nov 24.

4.

Exome-wide single-base substitutions in tissues and derived cell lines of the constitutive Fhit knockout mouse.

Paisie CA, Schrock MS, Karras JR, Zhang J, Miuma S, Ouda IM, Waters CE, Saldivar JC, Druck T, Huebner K.

Cancer Sci. 2016 Apr;107(4):528-35. doi: 10.1111/cas.12887. Epub 2016 Feb 23.

5.

Replicative Stress and the FHIT Gene: Roles in Tumor Suppression, Genome Stability and Prevention of Carcinogenesis.

Karras JR, Paisie CA, Huebner K.

Cancers (Basel). 2014 Jun 4;6(2):1208-19. doi: 10.3390/cancers6021208.

6.

Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.

Gasparini P, Fassan M, Cascione L, Guler G, Balci S, Irkkan C, Paisie C, Lovat F, Morrison C, Zhang J, Scarpa A, Croce CM, Shapiro CL, Huebner K.

PLoS One. 2014 Feb 5;9(2):e88525. doi: 10.1371/journal.pone.0088525. eCollection 2014.

7.

Fhit deficiency-induced global genome instability promotes mutation and clonal expansion.

Miuma S, Saldivar JC, Karras JR, Waters CE, Paisie CA, Wang Y, Jin V, Sun J, Druck T, Zhang J, Huebner K.

PLoS One. 2013 Nov 14;8(11):e80730. doi: 10.1371/journal.pone.0080730. eCollection 2013.

8.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.

J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.

9.

A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation.

Wu Y, Feng X, Jin Y, Wu Z, Hankey W, Paisie C, Li L, Liu F, Barsky SH, Zhang W, Ganju R, Zou X.

Cancer Prev Res (Phila). 2010 Jul;3(7):818-28. doi: 10.1158/1940-6207.CAPR-09-0213. Epub 2010 Jun 29.

10.

CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.

Vasilatos SN, Broadwater G, Barry WT, Baker JC Jr, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):901-14. doi: 10.1158/1055-9965.EPI-08-0875. Epub 2009 Mar 3.

11.

ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Baker JC Jr, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1884-90. doi: 10.1158/1055-9965.EPI-07-2696.

12.

Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF.

Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC Jr, Ibarra C, Brander DM, Paisie C, Case NR, Gauthier M, Reynolds PA, Dietze E, Ostrander J, Scott V, Wilke LG, Yee L, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Tlsty TD, Seewaldt VL.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6834-41.

13.

Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.

Bean GR, Ibarra Drendall C, Goldenberg VK, Baker JC Jr, Troch MM, Paisie C, Wilke LG, Yee L, Marcom PK, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Scott V, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):50-6.

Supplemental Content

Loading ...
Support Center